Investment Thesis
CapsoVision is a pre-commercial medical device company burning cash at an unsustainable rate, with operating losses of $7.1M against revenue of only $2.8M. While gross margins of 47.6% suggest product viability, the company's 254% negative operating margin and -$6.1M operating cash flow indicate critical challenges in reaching profitability. The company has liquidity runway but faces severe operational stress without evidence of a credible path to cash flow positivity.
Strengths
- Strong liquidity position with 4.57x current ratio and 3.92x quick ratio providing operational runway
- Healthy gross margin of 47.6% indicates underlying product economics are viable despite commercialization challenges
- No long-term debt reduces financial leverage risk and provides restructuring flexibility
Risks
- Massive operating losses of $7.1M against only $2.8M revenue represent fundamentally unsustainable unit economics and business model stress
- Negative operating cash flow of $6.1M will deplete stockholders' equity in 3-4 years at current burn rate without intervention
- Medical device commercialization timelines are uncertain with unclear evidence of accelerating adoption or path to positive cash flow
Key Metrics to Watch
- Quarterly revenue growth acceleration and customer concentration/retention metrics
- Operating cash flow improvement trajectory and runway in quarters
- Gross margin sustainability and whether scale reduces fixed cost burden
Financial Metrics
Revenue
2.8M
Net Income
-7.0M
EPS (Diluted)
$-0.15
Free Cash Flow
-6.1M
Total Assets
25.9M
Cash
N/A
Profitability Ratios
Gross Margin
47.6%
Operating Margin
-254.0%
Net Margin
-251.9%
ROE
-34.8%
ROA
-27.1%
FCF Margin
-219.0%
Balance Sheet & Liquidity
Current Ratio
4.57x
Quick Ratio
3.92x
Debt/Equity
0.00x
Debt/Assets
22.1%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:58:26.474032 |
Data as of: 2026-03-31 |
Powered by Claude AI